| PROGENIKA BIOPHARMA, S.A. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110098191 | IN VITRO METHODS FOR DETECTING RENAL CANCER - The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression. | 04-28-2011 |
| 20110045997 | METHOD AND PRODUCT FOR "IN VITRO" GENOTYPING WITH APPLICATIONS IN ANTI-AGEING MEDICINE - The invention relates to an “in vitro” method for determining the global genetic risk a subject has of developing a pathology associated with aging. Said method is based on the combination of particular genetic risks of developing common pathologies associated with aging. Said particular genetic risks are determined from the results obtained from the simultaneous genotyping of certain genetic variations associated with said pathologies associated with aging and the main objective of which is the use thereof in anti-aging medicine. | 02-24-2011 |
| 20100068710 | METHODS AND PRODUCTS FOR IN VITRO GENOTYPING - An in vitro method for genotyping genetic variations in an individual, and products for use in the method. | 03-18-2010 |
| 20080274968 | IN VITRO METHODS FOR DETECTING RENAL CANCER - The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression. | 11-06-2008 |
